Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas

NCT07544654 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07544654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07544654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Recruiting
Start date
July 10, 2026
Completion date
December 13, 2029
Enrollment
390 (estimated)
Sites
166

Conditions

As the registry lists them; a condition with its own page is linked.

extrapulmonary neuroendocrine cancer (epnec)